Kusunose K, Imai T, Tanaka A, et al. - Canagliflozin exhibited a trend of lower NT-pro BNP levels in the subgroup with lower left ventricular (LV) diastolic function compared with glimepiride.

• According to the findings of this investigation, the positive benefits of canagliflozin treatment may change depending on the severity of LV diastolic dysfunction.

• In the CANDLE trial, patients (n = 233) were randomly assigned to either an add-on canagliflozin (n = 113) or glimepiride treatment groups (n = 120).

• The geometric mean change in NT-proBNP level from baseline to 24 weeks in the canagliflozin group was 0.98 and 1.07 in the glimepiride group.

• The change ratio with canagliflozin/glimepiride was 0.93.

• The reaction of an increase in NT-proBNP levels was investigated using responder analyses.

• Although the subgroup analyses for septal annular velocity (SEP-e′) revealed no significant differences in treatment effect, the subgroup with SEP-e′ < 4.7 cm/s revealed a connection with reduced NT-proBNP levels in the canagliflozin group compared with the glimepiride group.